Margarita D. Andreeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Margarita D. Andreeva has a total of 294 co-authors. Here are the top co-authors by number of shared publications:
- Mariya Igorevna Yarmolinskaya
D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, St. Petersburg, Russia
4 shared publications - Dolgushina N.V. Dolgushina
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
3 shared publications - Elena V. Enkova
Voronezh State Medical University named after N.N. Burdenko
3 shared publications - Margarita G. Novosartian
Kuban State Medical University, Health Ministry of Russian Federation
3 shared publications - Natalya Vladimirovna Artymuk
Kemerovo State Medical University
3 shared publications Semenov Yu.A. Semenov
3 shared publications
Latest Publications
- 13 July 2026
- Published by IRBIS in Obstetrics, Gynecology and Reproduction
- Vol. 20 (3) , 409-419
Latent thrombophilic conditions in pregnant and reproductive-age women with an adverse cerebrovascular history and a high risk of acute cerebrovascular events
Aim: to assess the prevalence and pattern of latent thrombophilic conditions in pregnant and reproductive-age women with an adverse cerebrovascular history, as well as in patients at high risk of acute cerebrovascular events (ACVEs) identified using a previously developed prognostic model, based on a comprehensive clinical and hemostasiological analysis. Materials and Methods. A two-stage observational study was conducted, consisting of sequential retrospective and prospective phases. In the retrospective phase, data from 50 patients with ACVEs that had occurred during pregnancy, in the early postpartum period, or outside gestation were analyzed; 30 clinically healthy pregnant women were included in control group. Based on the retrospective data, a prognostic model for cerebrovascular risk stratification had previously been developed; in the present study, this model was used solely as a tool to identify high-risk patients. In the prospective phase, 45 pregnant and reproductive-age women with ACVEs history or a high risk of their development, as identified by the above model, as well as 30 clinically healthy pregnant women, were examined. All patients underwent an extended clinical and hemostasiological evaluation, including assessing genetic thrombophilia, natural anticoagulant deficiencies, antiphospholipid antibodies (aPL), homocysteine levels, metalloproteinase ADAMTS-13 activity, anti-ADAMTS-13 antibodies, as well as parameters of the vWF/ADAMTS-13 axis. Results. In the retrospective phase, inherited and acquired forms of thrombophilia were detected significantly more often in patients with ACVEs than in control group, 84.0 % versus 6.7 % cases, respectively. Pattern of cerebrovascular events was featured with ischemic stroke diagnosed in 58.0 % patients, whereas cerebral venous thrombosis – in 42.0 % cases. In prospective group, genetically determined thrombogenic abnormalities were detected in 35.6 % patients, criterial aPLs were detected in 28.9 %, hyperhomocysteinemia – in 15.6 %, reduced ADAMTS-13 activity – in 11.1 %, anti-ADAMTS-13 antibodies – in 26.7 %, and elevated von Willebrand factor levels – in 28.9 %. Combined thrombophilia was identified in 35.6 % patients in the prospective group, suggesting the multifactorial nature of prothrombotic predisposition. Conclusion. Latent thrombophilic conditions are frequently detected in pregnant and reproductive-age women with ACVEs history, as well as in patients at ACVE high risk, and often have a combined pattern involving both genetically determined and acquired hemostatic disorders. These findings substantiate a need for extended clinical and hemostasiological assessment in this category of patients at the stage of pregnancy planning and during pregnancy to improve risk stratification and individualize prevention of thrombotic complications.
- 13 July 2026
- Published by IRBIS in Obstetrics, Gynecology and Reproduction
- Vol. 20 (3) , 409-419
Latent thrombophilic conditions in pregnant and reproductive-age women with an adverse cerebrovascular history and a high risk of acute cerebrovascular events
Aim: to assess the prevalence and pattern of latent thrombophilic conditions in pregnant and reproductive-age women with an adverse cerebrovascular history, as well as in patients at high risk of acute cerebrovascular events (ACVEs) identified using a previously developed prognostic model, based on a comprehensive clinical and hemostasiological analysis. Materials and Methods. A two-stage observational study was conducted, consisting of sequential retrospective and prospective phases. In the retrospective phase, data from 50 patients with ACVEs that had occurred during pregnancy, in the early postpartum period, or outside gestation were analyzed; 30 clinically healthy pregnant women were included in control group. Based on the retrospective data, a prognostic model for cerebrovascular risk stratification had previously been developed; in the present study, this model was used solely as a tool to identify high-risk patients. In the prospective phase, 45 pregnant and reproductive-age women with ACVEs history or a high risk of their development, as identified by the above model, as well as 30 clinically healthy pregnant women, were examined. All patients underwent an extended clinical and hemostasiological evaluation, including assessing genetic thrombophilia, natural anticoagulant deficiencies, antiphospholipid antibodies (aPL), homocysteine levels, metalloproteinase ADAMTS-13 activity, anti-ADAMTS-13 antibodies, as well as parameters of the vWF/ADAMTS-13 axis. Results. In the retrospective phase, inherited and acquired forms of thrombophilia were detected significantly more often in patients with ACVEs than in control group, 84.0 % versus 6.7 % cases, respectively. Pattern of cerebrovascular events was featured with ischemic stroke diagnosed in 58.0 % patients, whereas cerebral venous thrombosis – in 42.0 % cases. In prospective group, genetically determined thrombogenic abnormalities were detected in 35.6 % patients, criterial aPLs were detected in 28.9 %, hyperhomocysteinemia – in 15.6 %, reduced ADAMTS-13 activity – in 11.1 %, anti-ADAMTS-13 antibodies – in 26.7 %, and elevated von Willebrand factor levels – in 28.9 %. Combined thrombophilia was identified in 35.6 % patients in the prospective group, suggesting the multifactorial nature of prothrombotic predisposition. Conclusion. Latent thrombophilic conditions are frequently detected in pregnant and reproductive-age women with ACVEs history, as well as in patients at ACVE high risk, and often have a combined pattern involving both genetically determined and acquired hemostatic disorders. These findings substantiate a need for extended clinical and hemostasiological assessment in this category of patients at the stage of pregnancy planning and during pregnancy to improve risk stratification and individualize prevention of thrombotic complications.
- 31 January 2024
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 1_2024, 50-66
Surgical management of placenta accreta spectrum in the Russian Federation (a pilot multicenter study)
- 31 January 2024
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 1_2024, 50-66
Surgical management of placenta accreta spectrum in the Russian Federation (a pilot multicenter study)
- Open Access
- 5 March 2023
- Published by IRBIS in Obstetrics, Gynecology and Reproduction
- Vol. 17 (1) , 45-52
Assessing efficacy and safety of iron (III) hydroxide oligoisomaltosate in reproductive-age women with iron deficiency anemia
Assessing efficacy and safety of iron (III) hydroxide oligoisomaltosate in reproductive-age women with iron deficiency anemia
- 5 March 2023
- Published by IRBIS in Obstetrics, Gynecology and Reproduction
- Vol. 17 (1) , 45-52
Open AccessAssessing efficacy and safety of iron (III) hydroxide oligoisomaltosate in reproductive-age women with iron deficiency anemia
Assessing efficacy and safety of iron (III) hydroxide oligoisomaltosate in reproductive-age women with iron deficiency anemia
- 28 February 2023
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 2_2023, 108-116
Efficacy of a combined drug containing ferrous fumarate and folic acid in anemia in the second trimester of pregnancy: results of a multicenter study
- 28 February 2023
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 2_2023, 108-116
Efficacy of a combined drug containing ferrous fumarate and folic acid in anemia in the second trimester of pregnancy: results of a multicenter study
- Open Access
- 1 January 2023
- Published by Altay State Medical University in Bulletin of Medical Science
- Vol. 30 (2) , 116-122
ASSESSING THE ACTUAL APPLICATION OF CLINICAL GUIDELINES FOR PREVENTING VENOUS THROMBOEMBOLIC COMPLICATIONS DURING PREGNANCY, CHILDBIRTH, AND POSTPARTUM PERIOD
Given the critical nature of venous thromboembolic complications (VTEC) in pregnant women, it is vital to review the preventive strategies for deep vein thrombosis and pulmonary embolism during pregnancy, delivery, and the early postpartum period, as outlined by the current clinical guidelines in the Russian Federation. Through our own experience with these guidelines, we have come to the realization that a dynamic assessment of VTEC risk, along with a personalized approach to prescribing antithrombotic agents throughout gestation and the postpartum phase, is indispensable.
- 1 January 2023
- Published by Altay State Medical University in Bulletin of Medical Science
- Vol. 30 (2) , 116-122
Open AccessASSESSING THE ACTUAL APPLICATION OF CLINICAL GUIDELINES FOR PREVENTING VENOUS THROMBOEMBOLIC COMPLICATIONS DURING PREGNANCY, CHILDBIRTH, AND POSTPARTUM PERIOD
Given the critical nature of venous thromboembolic complications (VTEC) in pregnant women, it is vital to review the preventive strategies for deep vein thrombosis and pulmonary embolism during pregnancy, delivery, and the early postpartum period, as outlined by the current clinical guidelines in the Russian Federation. Through our own experience with these guidelines, we have come to the realization that a dynamic assessment of VTEC risk, along with a personalized approach to prescribing antithrombotic agents throughout gestation and the postpartum phase, is indispensable.
- Open Access
- 15 April 2022
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 24 (2) , 101-107
Clinical effect of the combination of myoinositol and D-chiroinositol in the ratio 5:1 with manganese and folic acid on female reproductive function in patients with anovulatory infertility in patients with abnormal menstrual cycles and obesity
Aim. Effect of daily use of the combination of myoinositol and D-chiroinositol with manganese and folic acid (Dikirogen) on the onset of a regular menstrual cycle, ovulation, pregnancy, tolerance and satisfaction of the study participants. Materials and methods. The study involved 60 women aged 40 years and younger, the average age was 30,933,79 years. Duration of taking Dikirogen was 1703 days, participants observation was 1803 days. Body mass index, waist circumference (WC), ultrasound of the pelvic organs and ovaries, assessment of hirsutism (Ferryman-Gallway scale), acne severity (Cook questionnaire), depressive symptoms (Hamilton scale), quality of life (SF36 questionnaire) were performed during the study. Results. The pregnancy rate at the end of the study was 31.7%. During the daily using of the Dikirogen, there was a decrease in WC (p=0,007), the severity of acne (p=0,002) and the number of points on the Hamilton scale (p=0,04). Also there was a increase in the number of points on the SF36 questionnaire (p=0,0001). 93.33% of the woman has been reported that the Dikirogen was well tolerated. Conclusion. Dikirogen is an optimal doses chemical composition, selected taking into account the synergism of the components and the daily requirement, and it is effective in treatment for women with anovulatory infertility.
- 15 April 2022
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 24 (2) , 101-107
Open AccessClinical effect of the combination of myoinositol and D-chiroinositol in the ratio 5:1 with manganese and folic acid on female reproductive function in patients with anovulatory infertility in patients with abnormal menstrual cycles and obesity
Aim. Effect of daily use of the combination of myoinositol and D-chiroinositol with manganese and folic acid (Dikirogen) on the onset of a regular menstrual cycle, ovulation, pregnancy, tolerance and satisfaction of the study participants. Materials and methods. The study involved 60 women aged 40 years and younger, the average age was 30,933,79 years. Duration of taking Dikirogen was 1703 days, participants observation was 1803 days. Body mass index, waist circumference (WC), ultrasound of the pelvic organs and ovaries, assessment of hirsutism (Ferryman-Gallway scale), acne severity (Cook questionnaire), depressive symptoms (Hamilton scale), quality of life (SF36 questionnaire) were performed during the study. Results. The pregnancy rate at the end of the study was 31.7%. During the daily using of the Dikirogen, there was a decrease in WC (p=0,007), the severity of acne (p=0,002) and the number of points on the Hamilton scale (p=0,04). Also there was a increase in the number of points on the SF36 questionnaire (p=0,0001). 93.33% of the woman has been reported that the Dikirogen was well tolerated. Conclusion. Dikirogen is an optimal doses chemical composition, selected taking into account the synergism of the components and the daily requirement, and it is effective in treatment for women with anovulatory infertility.
- 23 September 2021
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 9_2021
Socioeconomic benefits from adequate correction of iron deficiency in pregnant women
- 23 September 2021
- Published by Bionika Media in Akusherstvo i ginekologiia
- Vol. 9_2021
Socioeconomic benefits from adequate correction of iron deficiency in pregnant women
- Open Access
- 9 September 2021
- Published by IRBIS in Obstetrics, Gynecology and Reproduction
- Vol. 15 (4) , 351-359
A multidisciplinary approach to the preterm birth
Introduction. Rate of factors affecting preterm birth development has not been fully elucidated. The assessment was carried out by identifying 1-2 causes used to build up prognosis.Aim: to identify most relevant risk factors for preterm birth and assess their impact on pregnancy.Materials and Methods. The prospective comparative study was conducted that included group 1 - 36 women with term pregnancy, group 2 - 35 with preterm labor. Establishment of the menstrual cycle has been studied by assessing reproductive, somatic history, and course of current pregnancy.Results. The postpartum women from group 2 were characterized by older age (30.42 ± 6.19 years; p = 0.038). The groups differed by the age of menarche: in group 2, its onset was recorded earlier (11.31 ± 0.79 years), showing shorter duration of menstruation (4.25 ± 1.26 days) as well as menstrual cycle (27.71 ± 3.46 days). Infections in puberty were substantially more frequent in postpartum women from group 2: group 2 vs. group 1 - in 21 vs. 8 postpartum women (p < 0.001); a history of urinary tract infections was also more common in group 2 (in 17 puerperas; p = 0.003), that is also typical for cases resulting in preterm pregnancy. The causative agent of bacterial vaginosis in group 2 was more often presented by Atopobium vaginae (in 17 puerperas; p = 0.0001), with Gardnerella vaginalis found less frequently (in 13 puerperas; p = 0.024), which is important to know for selecting proper therapy. During full-term pregnancy, the Lactobacillus crispatus strain, that determines vaginal health, was excreted significantly more often (in 29 puerperas; p = 0.009). Anemia affecting the antenatal fetal development and the course of labor was significantly more frequent in group 2 (in 22 puerperas; p < 0.001).Conclusion. While planning pregnancy, it is necessary to take into account the age, menstrual cycle features, history of former infections, vaginal microbiota features, as well as conduct proper therapy and prevention in pregravid period.
- 9 September 2021
- Published by IRBIS in Obstetrics, Gynecology and Reproduction
- Vol. 15 (4) , 351-359
Open AccessA multidisciplinary approach to the preterm birth
Introduction. Rate of factors affecting preterm birth development has not been fully elucidated. The assessment was carried out by identifying 1-2 causes used to build up prognosis.Aim: to identify most relevant risk factors for preterm birth and assess their impact on pregnancy.Materials and Methods. The prospective comparative study was conducted that included group 1 - 36 women with term pregnancy, group 2 - 35 with preterm labor. Establishment of the menstrual cycle has been studied by assessing reproductive, somatic history, and course of current pregnancy.Results. The postpartum women from group 2 were characterized by older age (30.42 ± 6.19 years; p = 0.038). The groups differed by the age of menarche: in group 2, its onset was recorded earlier (11.31 ± 0.79 years), showing shorter duration of menstruation (4.25 ± 1.26 days) as well as menstrual cycle (27.71 ± 3.46 days). Infections in puberty were substantially more frequent in postpartum women from group 2: group 2 vs. group 1 - in 21 vs. 8 postpartum women (p < 0.001); a history of urinary tract infections was also more common in group 2 (in 17 puerperas; p = 0.003), that is also typical for cases resulting in preterm pregnancy. The causative agent of bacterial vaginosis in group 2 was more often presented by Atopobium vaginae (in 17 puerperas; p = 0.0001), with Gardnerella vaginalis found less frequently (in 13 puerperas; p = 0.024), which is important to know for selecting proper therapy. During full-term pregnancy, the Lactobacillus crispatus strain, that determines vaginal health, was excreted significantly more often (in 29 puerperas; p = 0.009). Anemia affecting the antenatal fetal development and the course of labor was significantly more frequent in group 2 (in 22 puerperas; p < 0.001).Conclusion. While planning pregnancy, it is necessary to take into account the age, menstrual cycle features, history of former infections, vaginal microbiota features, as well as conduct proper therapy and prevention in pregravid period.